Washington: For the first time a vaccine was designed to stop three common pathogens of traveler's diarrhea.
A new study conducted by a chemist from the University of Guelph, Mario Monteiro, has confirmed this.
Monteiro says his 3-in-1 approach to developing a new vaccine could save lives in developing countries, where the three common pathogens kill more than 100,000 children under the age of five.
The study appears in the journal vaccine.
The study found that the conjugated vaccine binds pathogenic E. coli proteins with Shigella and Campylobacter jejuni sugars. These are the three bugs that contribute mainly to the global spread of the disease.
In tests with mice, the vaccine provided immunity against all three pathogens. Up to now, no authorized vaccines existed against any of these pathogens.
In 2009, a sugar-based vaccine was developed by Monteiro against only campylobacter and is currently undergoing human trials.
"We are targeting three pathogens At the same time, instead of three shots, maybe you only need one," said Monteiro
Monteiro added that further research is needed to determine the optimal amount of protein And sugars in the vaccine to make it more efficient.